|
Recently, it has been reported that a serious adverse reaction called nephrogenic systemic fibrosis (NSF) may occur after exposure to the extracellular nonionic low osmolar gadolinium-based contrast agent gadodiamide (Omniscan®, GE Health Diagnostic, Amersham, United Kingdom). Nephrogenic systemic fibrosis was recognized in 1997 in California. The typical patient is middle-aged and has end-stage renal disease (ESRD). Most patients, but not all, are on regular dialysis treatment. The typical course begins with swelling of the extremities followed by severe skin induration (hardening of the skin). The skin induration may be aggressive and associated with constant pain, muscle restlessness, and loss of skin flexibility. In some cases, NSF leads to serious physical disability including wheelchair requirement. NSF was initially observed in and thought to solely affect the skin—therefore, it was initially called nephrogenic fibrosing dermopathy—but it is now known that several organs such as liver, lungs, muscles and heart may be involved. Organ involvement may explain the suspected increased mortality of NSF patients.
If you or someone you know is suffering, or has suffered from, NSF, fill out the form below for a free assessment of the case.
Injured Person Information:
Accident / Injury Information:
Case Description*
Please explain exactly what happened, trying to state
as thoroughly as possible who you believe was responsible
and why you believe that person was negligent:
|
Please explain the full extent of the victims injuries:
|
Comments / Additional Information
Is there anything else that would assist us in
understanding the facts of your case?
|
| 
